The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast. Moderna (NASDAQ: MRNA) has fallen ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...

New research shows promising signs that the Pfizer and Moderna vaccines might offer protection for a longer time than previously thought. And that protection could potentially last for years Health ...

Add Yahoo as a preferred source to see more of our stories on Google. A nurse draws up doses of the Moderna COVID-19 for a vaccination clinic in St. Helena in 2021. Moderna is offering a new, low-dose ...

The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies that neutralize the intended SARS-CoV-2 variant target among recipients, according to a press release from ...

The EMA approved Moderna's mRNA COVID-19 and flu vaccine, but US political battles and funding cuts threaten the future of mRNA vaccine innovation. Talha Burki reports.

Six years after early vaccine trials, the legacy of COVID-19 shots reflects science, public debate, and how perceptions ...

Feb 27 (Reuters) - Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the ‌first single shot to protect people ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...